Catalog Number
ACM91524151
Description
Irloxacin is a new quinolone derivative, and shows greater activity with an acid pH. It has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria. In vitro activity of irloxacin against mycobacteria (20 M. tuberculosis, 17 M. avium, 5 Mycobacterium bovis, 5 Mycobacterium chelonae, 5 Mycobacterium fortuitum and 1 Mycobacterium gadium) using the Bactec at pH 6.8 and 5.0, with other quinolones (ofloxacin, ciprofloxacin, pefloxacin and 27753 RP) were compared. All quinolones tested showed good activity against mycobacteria at pH 6.8 and 5.0. Irloxacin at pH 5.0 had a greater activity against M. avium.
Synonyms
E 3432; E3432; E-3432; Irloxacin; Pirfloxacin
IUPAC Name
3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)-
Molecular Formula
C16H13FN2O3
Canonical SMILES
O=C(C1=CN(CC)C2=C(C=C(F)C(N3C=CC=C3)=C2)C1=O)O
InChI
InChI=1S/C16H13FN2O3/c1-2-18-9-11(16(21)22)15(20)10-7-12(17)14(8-13(10)18)19-5-3-4-6-19/h3-9H,2H2,1H3,(H,21,22)
InChI Key
RZLHGQLYNZQZQQ-UHFFFAOYSA-N
Solubility
To be determined
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Alternative CAS
122949-49-9 (sodium); 91524-15-1 (free acid)
Biological Target
Irloxacin (Pirfloxacin) is a quinolone antibacterial agent that shows greater activity with an acidic pH and has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria.
Drug Formulation
To be determined
Elemental Analysis
C, 64.00; H, 4.36; F, 6.33; N, 9.33; O, 15.98
HS Tariff Code
2934.99.9001
In Vivo Activity
Embryotoxicity studies on irloxacin (6-fluorine-7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid, CAS-91524-15-1), a new fluoroquinolone antibacterial agent, were performed in rats and rabbits. Oral administration of irloxacin during the fetal period of organogenesis to pregnant rats and rabbits at dose levels of up to 1000 and 350 mg/kg/d, respectively, elicited no evidence of teratogenicity. During the first days of treatment, transient stasis in body weight increase was observed in rat dams receiving doses of 350 or 1000 mg/kg/d, and reduced food consumption was observed in those receiving 1000 mg/kg/d. Necropsy on day 20 of gestation showed dosage related increase in liver and kidney weights in all rat treated groups. Rabbit dams receiving 350 mg/kg/d showed during the first days of treatment decrease in body weight, and decreased food consumption and faecal output. Also, four females receiving 350 mg/kg/d aborted between days 18 and 20 of gestation. Rat fetuses in the 350 and 1000 mg/kg/d showed decreased body weight, and a decrease in placental weights was observed in the 1000 mg/kg/d group. No retardations or malformations were observed in rat or rabbit fetuses at any tested dose level.
Reference: Arzneimittelforschung. 2003;53(2):121-5. https://pubmed.ncbi.nlm.nih.gov/12642968/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).
Download
